In the study, one group receives letrozole together with the usual fertility treatment, while the other group receives the usual treatment without letrozole. Treatment is given during one egg collection cycle, and any embryos made from that cycle may be transferred fresh or frozen and used later within about one year. The study then follows the pregnancy outcomes after these embryo transfers. The study also looks at related conditions such as adenomyosis, a condition in which tissue similar to the lining of the womb grows into the womb muscle.

The study is designed to see whether letrozole can improve reproductive results in this setting and to collect information on pregnancy, birth, and any problems that may happen during pregnancy. It also records pain after egg collection and quality of life around the time of embryo transfer.

The study will compare two different doses of vipoglanstat with placebo to see which works best. Participants will take the medication by mouth in capsule form. During the study, women will be asked to record their pain levels, particularly focusing on pain during days when they are not menstruating. The study will also look at pain during menstrual bleeding days, which is called dysmenorrhea. Information will be collected about any use of pain relief medications, including opioid medications, which are strong pain relievers. The study will also measure how endometriosis affects quality of life and daily activities using questionnaires.

The treatment period will last for four months, during which participants will attend several visits. Throughout the study, doctors will monitor participants for any side effects and will perform regular safety checks including blood tests and urine tests. The study will track changes in pain levels from the beginning of treatment to the end of the four-month period to determine if vipoglanstat is effective in reducing endometriosis-related pain.

The study will compare two different treatments. One group will receive cabergoline (0.5 mg taken twice per week), while the other group will receive standard treatment with either dienogest or combined birth control pills. The treatment period will last for 6 months.

During the study, doctors will monitor changes in the endometriosis growths using various imaging techniques such as ultrasound and magnetic resonance imaging. They will also track how well the treatment helps with pain and other symptoms. The study will also look at how the medications affect hormone levels in the body and overall quality of life for people with endometriosis.

The purpose of the study is to explore how effective this new imaging method is in identifying and characterizing endometriosis lesions, especially in relation to the pain experienced by patients. Participants in the study will undergo this imaging test, and the results will be compared to other methods like MRI to see how well it works. The study will also look at how the findings from the imaging relate to the level of pain and other characteristics of the lesions.

Throughout the study, participants will have the [18F]-FES PET/CT scan, and the information gathered will help researchers understand more about endometriosis and how to better diagnose it. The study aims to provide insights that could lead to improved ways of detecting and managing this condition in the future.

During the study, participants will undergo a PET scan using a substance called fludeoxyglucose (18F), which helps highlight areas of concern in the body. This is a solution that is injected into the body and is designed to make the PET scan images clearer. The study will also use a solution called Furosemide, which is a medication that helps the body get rid of excess fluid, and Omnipaque, a contrast agent that improves the visibility of internal structures in imaging tests.

The purpose of the study is to determine if the PET scan can accurately diagnose endometriosis lesions compared to traditional surgical methods. Participants will receive these injections and undergo the PET scan, and the results will be compared to what is found during surgery. This research could help improve the way endometriosis is diagnosed and managed in the future.

The purpose of the study is to see if using triptorelin before a procedure called frozen embryo transfer (FET) can improve pregnancy rates in women undergoing assisted reproductive technology (ART). In this study, some participants will receive the triptorelin treatment, while others will receive a placebo. The study will monitor the clinical pregnancy rates, which means checking for a fetal heartbeat during an ultrasound at the final visit.

Participants will be followed throughout the study to observe the number of successful embryo implantations, any miscarriages, and any side effects related to low estrogen levels, such as hot flashes or mood swings. The study aims to provide valuable information on whether this treatment can help improve outcomes for women with endometriosis and/or adenomyosis who are trying to conceive through ART.

The purpose of the study is to see how well these treatments work in reducing the severity of endometriosis. Participants will receive one of the treatments or a placebo, which looks like the treatment but does not contain the active medication. The study will involve regular check-ups and assessments, including imaging tests like MRI (Magnetic Resonance Imaging), to monitor changes in the condition. Some participants may also undergo a procedure called laparoscopy, which is a type of surgery that allows doctors to look inside the abdomen to assess the severity of endometriosis.

The study will last for a period of time, during which participants will be closely monitored by healthcare professionals. The goal is to gather information on how the treatments affect the symptoms and progression of endometriosis, providing valuable insights into potential new therapies for this condition. Participants will be required to switch from their usual pain medications to those allowed by the study protocol to ensure accurate results.

The main goal of the study is to assess how an 8-hour infusion of esketamine affects the pain experienced by patients with endometriosis. Participants will receive either the esketamine infusion or a placebo. The study will measure pain levels using a numeric rating scale, where patients rate their pain on a scale from 0 (no pain) to 10 (worst pain imaginable). This will help determine if esketamine can effectively reduce chronic pelvic pain in these patients.

Throughout the study, participants will be monitored for any changes in their pain levels and overall treatment experience, including any side effects. The study will also look at other factors such as quality of life and any depressive symptoms. The results will help understand the potential benefits and risks of using esketamine for managing chronic pain in endometriosis, providing valuable information for future treatment options.

Participants in the study will receive either cabergoline or a placebo. Cabergoline is a medication that works by affecting the levels of certain chemicals in the brain, which can help manage symptoms of endometriosis. The study will observe the participants over a period of time to assess changes in their pain levels and fertility status. The goal is to determine if cabergoline can significantly reduce pain and improve the chances of conception in women with endometriosis.

Throughout the study, participants will be monitored to track their pain levels and any changes in their fertility. The study will also evaluate the overall impact of cabergoline on the quality of life for women dealing with endometriosis-related symptoms. This research is important for finding new ways to help women manage the symptoms of endometriosis and improve their chances of becoming pregnant.

Participants in the study will take the medication or placebo twice a day. The study will last for several months, during which participants will be asked to record their pain levels and any side effects they experience. The goal is to determine if OG-6219 can effectively reduce pain and to assess its safety for long-term use. The study will also monitor any changes in participants’ health through regular check-ups and tests.

In addition to OG-6219, the study involves the use of naproxen sodium, a common pain reliever, as a rescue medication for participants who need additional pain relief. The study aims to provide valuable information on whether OG-6219 can be a new treatment option for managing endometriosis-related pain, potentially improving the quality of life for those affected by this condition.